Centaurus Financial Inc. Has $169,000 Stock Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Centaurus Financial Inc. raised its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 7.0% in the third quarter, HoldingsChannel reports. The fund owned 14,996 shares of the company’s stock after purchasing an additional 985 shares during the quarter. Centaurus Financial Inc.’s holdings in Global X Genomics & Biotechnology ETF were worth $169,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. James J. Burns & Company LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 6.0% in the 3rd quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock worth $207,000 after purchasing an additional 1,038 shares in the last quarter. Corrado Advisors LLC raised its holdings in Global X Genomics & Biotechnology ETF by 3.0% during the third quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock worth $723,000 after buying an additional 1,894 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in shares of Global X Genomics & Biotechnology ETF by 10.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock valued at $707,000 after buying an additional 6,260 shares in the last quarter. Insight Advisors LLC PA grew its holdings in shares of Global X Genomics & Biotechnology ETF by 59.0% during the second quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock valued at $221,000 after buying an additional 7,861 shares during the last quarter. Finally, Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF during the third quarter worth about $122,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

GNOM opened at $10.83 on Thursday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $9.52 and a fifty-two week high of $12.53. The firm has a market capitalization of $79.17 million, a PE ratio of -4.61 and a beta of 1.03. The company’s 50-day moving average is $10.71 and its 200 day moving average is $10.85.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.